Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-60
SponsorPatel Hospital, Pakistan

About this trial

The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:

Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding.

Participants will:

Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery

Eligibility criteria

Qualifiers

Patients above 18 years of age AND

Undergoing Laparoscopic Sleeve Gastrectomy and MGB

Morbid obesity

Disqualifiers

Patients on anti-platelets/anti-coagulants

Patients with inherited or acquired bleeding disorders

Patients with any acute medical condition predisposing to bleeding

Hormonal contraceptives

Trial design

Treatments tested in this trial

  • Tranexamic Acid
  • Normal Saline (Placebo)

Treatment groups

140 Participants
are divided into 2 treatment groups

Sponsors and collaborators